Entering text into the input field will update the search result below

Encouraging results for StemCells' platform in AMD

Jun. 19, 2014 9:58 AM ETMicrobot Medical Inc. (MBOT) StockBy: Douglas W. House, SA News Editor24 Comments
  • Shares of StemCells (STEM +22.9%) jump on heavy volume in response to its announcement of positive interim results from the Phase 1/2 clinical trial of its HuCNS-SC human neural stem cell platform in dry age-related macular degeneration (AMD), albeit on a small group of seven patients.
  • The platform showed a 65% reduction in the rate of geographic atrophy (GA) in the study eye compared to the expected natural history of the disease and a 70% reduction in the rate of GA compared to the control eye. GA is the progressive loss of two retinal tissue layers (photoreceptors and retinal pigmented epithelium) that cause vision loss in dry AMD.
  • The company expects to initiate a Phase 2 proof-of-concept study later this year.

Recommended For You

About MBOT Stock

SymbolLast Price% Chg
Market Cap
PE
Yield (TTM)
Rev Growth (YoY)
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
MBOT--
Microbot Medical Inc.
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.